Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
While gastrointestinal tumors remain a multifactorial and prevalent group of malignancies commonly treated surgically in combination with chemotherapy and radiotherapy, advancements regarding immunotherapeutic approaches continue to occur. Entering a new era of immunotherapy focused on overcoming re...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/12/9945 |
| _version_ | 1797594348330680320 |
|---|---|
| author | Paulina Chmiel Katarzyna Gęca Adam Michalski Martyna Kłosińska Agnieszka Kaczyńska Wojciech P. Polkowski Zuzanna Pelc Magdalena Skórzewska |
| author_facet | Paulina Chmiel Katarzyna Gęca Adam Michalski Martyna Kłosińska Agnieszka Kaczyńska Wojciech P. Polkowski Zuzanna Pelc Magdalena Skórzewska |
| author_sort | Paulina Chmiel |
| collection | DOAJ |
| description | While gastrointestinal tumors remain a multifactorial and prevalent group of malignancies commonly treated surgically in combination with chemotherapy and radiotherapy, advancements regarding immunotherapeutic approaches continue to occur. Entering a new era of immunotherapy focused on overcoming resistance to preceding therapies caused the emergence of new therapeutic strategies. A promising solution surfaces with a V-domain Ig suppressor of T-cell activation (VISTA), a negative regulator of a T-cell function expressed in hematopoietic cells. Due to VISTA’s ability to act as both a ligand and a receptor, several therapeutic approaches can be potentially developed. A broad expression of VISTA was discovered on various tumor-growth-controlling cells, which proved to increase in specific tumor microenvironment (TME) conditions, thus serving as a rationale behind the development of new VISTA-targeting. Nevertheless, VISTA’s ligands and signaling pathways are still not fully understood. The uncertain results of clinical trials suggest the need for future examining inhibitor agents for VISTA and implicating a double immunotherapeutic blockade. However, more research is needed before the breakthrough can be achieved. This review discusses perspectives and novel approaches presented in the current literature. Based on the results of the ongoing studies, VISTA might be considered a potential target in combined therapy, especially for treating gastrointestinal malignancies. |
| first_indexed | 2024-03-11T02:22:26Z |
| format | Article |
| id | doaj.art-580f0b424f9e481e87447a268fc7cc86 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T02:22:26Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-580f0b424f9e481e87447a268fc7cc862023-11-18T10:46:20ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-06-012412994510.3390/ijms24129945Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System TumorsPaulina Chmiel0Katarzyna Gęca1Adam Michalski2Martyna Kłosińska3Agnieszka Kaczyńska4Wojciech P. Polkowski5Zuzanna Pelc6Magdalena Skórzewska7Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, PolandWhile gastrointestinal tumors remain a multifactorial and prevalent group of malignancies commonly treated surgically in combination with chemotherapy and radiotherapy, advancements regarding immunotherapeutic approaches continue to occur. Entering a new era of immunotherapy focused on overcoming resistance to preceding therapies caused the emergence of new therapeutic strategies. A promising solution surfaces with a V-domain Ig suppressor of T-cell activation (VISTA), a negative regulator of a T-cell function expressed in hematopoietic cells. Due to VISTA’s ability to act as both a ligand and a receptor, several therapeutic approaches can be potentially developed. A broad expression of VISTA was discovered on various tumor-growth-controlling cells, which proved to increase in specific tumor microenvironment (TME) conditions, thus serving as a rationale behind the development of new VISTA-targeting. Nevertheless, VISTA’s ligands and signaling pathways are still not fully understood. The uncertain results of clinical trials suggest the need for future examining inhibitor agents for VISTA and implicating a double immunotherapeutic blockade. However, more research is needed before the breakthrough can be achieved. This review discusses perspectives and novel approaches presented in the current literature. Based on the results of the ongoing studies, VISTA might be considered a potential target in combined therapy, especially for treating gastrointestinal malignancies.https://www.mdpi.com/1422-0067/24/12/9945VISTAVSIRPD-1HDies1tumor microenvironmentimmunotherapy |
| spellingShingle | Paulina Chmiel Katarzyna Gęca Adam Michalski Martyna Kłosińska Agnieszka Kaczyńska Wojciech P. Polkowski Zuzanna Pelc Magdalena Skórzewska Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors International Journal of Molecular Sciences VISTA VSIR PD-1H Dies1 tumor microenvironment immunotherapy |
| title | Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors |
| title_full | Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors |
| title_fullStr | Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors |
| title_full_unstemmed | Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors |
| title_short | Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors |
| title_sort | vista of the future novel immunotherapy based on the human v set immunoregulatory receptor for digestive system tumors |
| topic | VISTA VSIR PD-1H Dies1 tumor microenvironment immunotherapy |
| url | https://www.mdpi.com/1422-0067/24/12/9945 |
| work_keys_str_mv | AT paulinachmiel vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT katarzynageca vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT adammichalski vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT martynakłosinska vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT agnieszkakaczynska vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT wojciechppolkowski vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT zuzannapelc vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors AT magdalenaskorzewska vistaofthefuturenovelimmunotherapybasedonthehumanvsetimmunoregulatoryreceptorfordigestivesystemtumors |